ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IDYA IDEAYA Biosciences Inc

40.44
0.12 (0.30%)
Last Updated: 15:31:47
Delayed by 15 minutes
Share Name Share Symbol Market Type
IDEAYA Biosciences Inc NASDAQ:IDYA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.12 0.30% 40.44 40.29 40.41 40.60 39.90 40.28 173,561 15:31:47

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

01/04/2024 11:00am

PR Newswire (US)


IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart


From Mar 2024 to May 2024

Click Here for more IDEAYA Biosciences Charts.

SOUTH SAN FRANCISCO, Calif., April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

(PRNewsfoto/IDEAYA Biosciences, Inc.)

Stifel Virtual Targeted Oncology Forum
Tuesday, April 16th, 2024 at 12:00 PM ET

  • Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Benjamin Burnett, Ph.D., Managing Director, Equity Analyst

A live audio webcast of conference event, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host.  A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact

IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-april-2024-investor-relations-event-302101640.html

SOURCE IDEAYA Biosciences, Inc.

Copyright 2024 PR Newswire

1 Year IDEAYA Biosciences Chart

1 Year IDEAYA Biosciences Chart

1 Month IDEAYA Biosciences Chart

1 Month IDEAYA Biosciences Chart

Your Recent History

Delayed Upgrade Clock